Fertilo In Vitro Research Study

This study is testing a new approach called Fertilo for In Vitro Maturation (IVM), a process where eggs mature outside the body. Researchers want to see if Fertilo, which uses special ovarian support cells, is better than the currently approved MediCult IVM system for helping eggs mature. You may be eligible if you are a woman between 18 and 35 years old, have a BMI between 21-40, and are a candidate for IVF. The study will compare the number of ongoing pregnancies at 12 weeks of gestation between participants who use Fertilo and those who use MediCult IVM. The study aims to enroll 500 participants, but its current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 500 women. Participants will be divided into two groups, with one group using Fertilo and the other using MediCult IVM for egg maturation.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, ongoing pregnancy, will be measured at 12 weeks gestation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06858111

Fertilo In Vitro Research Study and Trial

Recruiting
PHASE3Ages 18–35Interventional
Gameto, Inc.
~500 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:FertiloMedicult IVM

At a glance

Recruiting sites
15 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Demonstration of the superiority of Fertilo compared to the currently approved MediCult IVM® for infertility treatment via IVF procedures.
Measured over 12 weeks gestation
In Vitro Maturation of Oocytes
15 sites across 7 states
Texas6
California2
Florida2
North Carolina2
Maryland1
New York1
Utah1

Opens a ready-to-send draft in your own email app — review before sending.

  • Demonstration of the superiority of Fertilo compared to the currently approved MediCult IVM® for infertility treatment via IVF procedures.12 weeks gestation

    Cumulative ongoing pregnancy from cycles initiated within 6 months post-randomization. The primary endpoint of ongoing pregnancy is assessed at 12 weeks gestation or later. Cumulative ongoing pregnancy is determined using the cumulative outcome of up to the first two embryo transfers. Subjects with a detectable fetal heartbeat, considered normal and healthy, are considered as having achieved an ongoing pregnancy. "Normal" will be determined as expected for the gestational age ranging from 110 bpm to 180 bpm and measured via ultrasound. Ongoing pregnancy is recorded as either a Yes or No for normal fetal heart rate present for each of the Subject's transfer cycles. Subjects without an ongoing pregnancy assessment are considered as a No unless a later observation indicates otherwise (i.e., a live birth). Cumulative ongoing pregnancy is derived as either a Yes, if at least one of the first two embryo transfers achieves an ongoing pregnancy, or a No otherwise.